Big Pharma Valuation
| PRM Stock | CAD 14.03 -0.37 -2.57% |
Against a market price of C$14.03, the model points to a Real Value near C$14.14 per share for Big Pharma, leaving the name fairly valued. The estimate draws on Big Pharma fundamentals, including return on equity of -16% and operating margin of 1.41%, together with its technical indicators and probability of bankruptcy. Like most valuation signals, this one reflects the idea that market price and underlying value can eventually converge. The main factors affecting Big Pharma's valuation include:
Recent filings indicate that Cash continues deteriorating. Big Pharma filed Cash of 927,576 for the preceding year. As of last week, Accounts Payable is anticipated to decline to approximately 298.4 K.
Price Book 1.0742 | Enterprise Value | Enterprise Value Ebitda -2.45 | Price Sales 6.4354 | Enterprise Value Revenue 6.6681 |
Fairly Valued
Today
Right now, the market is showing Very Low price fluctuation for Big Pharma. The current real value estimate for Big Pharma Split is based on a 3 months time horizon. Extending Big Pharma's horizon generally improves valuation accuracy and strengthens the model's predictive power.
Since Big Pharma is currently traded on the exchange, buyers and sellers determine the market value of Big Stock. Its market price can differ from intrinsic value, which may create an opportunity if price and value converge over time. | Historical | Market 14.03 | Real 14.14 | Hype 14.04 | Naive 13.98 |
The intrinsic value of Big Stock is an estimate of its true worth based on underlying business fundamentals. Common approaches to estimate Big Pharma's intrinsic value include DCF analysis, earnings-based multiples, and net asset value models.
A balanced view of Big Pharma Split must account for both its upside potential and its downside risk. Forecasting how Big stock performs depends on integrating both traditional fundamentals and market-based signals. Beyond Big Pharma's core financials, our valuation incorporates: Multiple valuation approaches for Big Pharma each tell part of the story. A disciplined investor reconciles outputs of different methods to arrive at a realistic estimate of Big Pharma's fair value.
Main Profitability Drivers
Big Pharma's operating margin of 141.20% reflects a business that retains a healthy share of each revenue dollar. Big Pharma generated 1.85 Million in revenue, producing -664,729 in gross profit (-35.9% gross margin) and -538,624 in net income. With ROE at -15.64% and ROA at -3.10%, these return measures help contextualize Big Pharma's profitability relative to its balance sheet. Big Pharma's profitability trends show broad deterioration, with the majority of key metrics declining year over year. The full picture is available through Big Pharma's complete profitability review to assess how these metrics compare over time.
Price Book 1.0742 | Gross Profit | Price Sales 6.4354 | Enterprise Value Revenue 6.6681 | Revenue |
Big Pharma Cash | 651,351 |
Valuation Framework, Methodology & Assumptions
Big Pharma is a micro-cap equity in Asset Management & Custody Banks, Financial Services categories. Revenue consistency stabilizes valuation context. Big Pharma currently trades at P/B of 1.07, P/S of 6.44.
Data shown for Big Pharma Split is aggregated from periodic company reporting and market reference feeds and normalized across reporting formats. Source publication cadence can introduce delays. Valuation outputs are model-derived and depend on published assumptions and reference inputs.
This content is curated and reviewed by:
Raphi Shpitalnik - Junior Member of Macroaxis Editorial BoardMore Resources for Big Stock Analysis
Other Information on Investing in Big Stock
Financial ratios for Big Pharma provide valuation context across profits, cash flow, and enterprise value. They help compare Big across valuation measures and peers.